Health Care · Pharmaceutical Preparations · Nasdaq · CIK 873303 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $15.54Day +0.68%Mkt cap $1.6B1Y −1.9%Off 52W high −38.6%Vol (1Y) 82.5%
Daily closing price, split-adjusted to the current basis; 3y shown of 5,294 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest27.0% of sh out |
| Days to cover9.2d |
| 13F net flow (QoQ)+6.94% |
| Top-10 13F concentration55.6% |
| Next report (est.)2026-08-05 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$2.18B |
| Earnings (TTM)$65.1M |
| ROE−53.5% |
| Net margin−32.5% |
| ROIC−47.2% |
| Debt / equity0.73× |
| Sales growth 3Y33.1% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−27.8% |
| 1Y−1.9% |
| 3Y−85.7% |
| 5Y−77.5% |
| 10Y−38.5% |
| Since incept. (ann.)+0.7% |
Total return through 2026-07-29 · series begins 2005-07-08. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)82.5% |
| Ann. volatility (3Y)79.7% |
| Sharpe (1Y)0.56 |
| Sharpe (3Y)−0.38 |
| Max drawdown (1Y)−38.7% |
| Max drawdown (3Y)−92.7% |
| Beta (3Y vs SPY)0.51 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| BlackRock, Inc. | 14.8M | $321M | 13.98% | +3.3% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 6.6M | $145M | 6.29% | new |
| STATE STREET CORP | 6.6M | $144M | 6.26% | +0.2% |
| AQR CAPITAL MANAGEMENT LLC | 6.4M | $139M | 6.09% | −17.5% |
| TWO SIGMA INVESTMENTS, LP | 4.6M | $100M | 4.35% | +88.1% |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.6M | $100M | 4.34% | new |
| FIRST TRUST ADVISORS LP | 4.1M | $90M | 3.92% | +107.6% |
| RA CAPITAL MANAGEMENT, L.P. | 3.9M | $85M | 3.70% | new |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-06 | $2.88 | — | $730.8M | −1.9% |
| 2025-12-31 | 2026-02-25 | −$3.93 | −362.0% | $442.9M | −32.7% |
| 2025-09-30 | 2025-11-03 | −$0.50 | −247.1% | $399.4M | −14.5% |
| 2025-06-30 | 2025-07-16 | $1.89 | +2600.0% | $611.1M | +68.4% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-05 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
All Other Segments 100%
business segments · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
